Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m(2)). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m(2)) yields comparable efficacy with 3-wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyota, Naomi, Tahara, Makoto, Mizusawa, Junki, Kodaira, Takeshi, Fujii, Hirofumi, Yamazaki, Tomoko, Mitani, Hiroki, Iwae, Shigemichi, Fujimoto, Yasushi, Onozawa, Yusuke, Hanai, Nobuhiro, Ogawa, Takenori, Hara, Hiroki, Monden, Nobuya, Shimura, Eiji, Minami, Shujiro, Fujii, Takashi, Tanaka, Kaoru, Homma, Akihiro, Yoshimoto, Seiichi, Oridate, Nobuhiko, Omori, Koichi, Ueda, Tsutomu, Okami, Kenji, Ota, Ichiro, Shiga, Kiyoto, Sugasawa, Masashi, Asakage, Takahiro, Saito, Yuki, Murono, Shigeyuki, Nishimura, Yasumasa, Nakamura, Kenichi, Hayashi, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197353/
https://www.ncbi.nlm.nih.gov/pubmed/35230884
http://dx.doi.org/10.1200/JCO.21.01293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197353/
https://www.ncbi.nlm.nih.gov/pubmed/35230884
http://dx.doi.org/10.1200/JCO.21.01293

Ejemplares similares